BBLG — Bone Biologics Corp

Nasdaq · Health Care · Health Care Equipment & Supplies · CIK 1419554 ·
Last close
$0.61
Market Cap
$1.67M
52W High
$1.54
52W Low
$0.58
ADV30
585,833
Next earnings
Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein in the United States. Its lead product is NELL-1/DBM medical device, an osteopromotive recombinant protein, which provides target specific control over bone regeneration. The company also develops NB1, a NELL-1/DBM fusion device for use in lumbar spinal fusion, as well as spine implants, non-union trauma cases, and osteoporosis applications. It serves spine surgeons and patients with a skeletal bone defect or bone-related condition in their spine. The company has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion by local administration, osteoporosis, and trauma applications. Bone Biologics Corporation was founded in 2004 and is headquartered in Burlington, Massachusetts.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 0 -805,054 -765,988 4,979,305 4,530,040 309,386
Dec 2025 0 -733,105 -684,643 5,796,135 5,334,322 418,587
Sep 2025 0 -715,274 -666,737 6,350,799 6,049,084 334,282
Jun 2025 0 -748,075 -740,519 7,002,216 6,640,468 406,142

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-2,569,307
Investing CF
Financing CF
$4,352,792
CapEx
Dividends Paid
Buybacks
EPS Diluted TTM
$-4.05
As of
2026-08-16

Balance + Analyst (yfinance extras)

Retained Earnings
$-88,896,357
Inventory
Receivables
$7,809
ST Investments
EBIT TTM
$-3,001,508
Pretax Income TTM
$-2,857,887
Interest Exp TTM
Analysts
1

Annual Trend (SEC EDGAR, last 5y)

Revenues vs Net Income (last 5y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 0 -3,234,942 -3,108,991 5,796,135 418,587 -2,691,150
Dec 2024 0 -4,219,161 -4,112,420 3,861,369 377,712 -4,124,935
Dec 2023 0 -9,428,303 -8,948,731 3,737,763 831,402 -9,555,904
Dec 2022 0 -3,665,173 -1,484,620 8,495,237 2,547,929 -3,566,913
Dec 2021

TTM Snapshot

Revenues TTM
NetIncome TTM
OpCashFlow TTM
Assets (Latest)
Forward EPS
$-0.67

Peers — same industry

TickerNameMarket CapLastDaily %
AEMD AETHLON MEDICAL INC $1.88M $2.64
ALUR ALLURION TECHNOLOGIES, INC. $2.01M $2.01
YBGJ Yubo International Biotech Ltd $2.03M $0.01
NUMD Nu-Med Plus, Inc. $2.03M $0.02
ESMC ESCALON MEDICAL CORP $1.33M $0.18

News headlines (Yahoo Finance, 1h cache)

BBLG Efficiency Improves as Crucial Trials Advance
2026-08-17 12:46 · Yahoo
Bone Biologics Extends rhNELL-1 Validated Shelf Life to 32 Months as NB1 Study Advances
2026-08-12 14:15 · Yahoo
Bone Biologics Achieves 32-Month Validated Shelf Life for rhNELL-1
2026-08-12 12:00 · Yahoo
BBLG Secures Financing for Critical Trials
2026-07-08 12:15 · Yahoo
Bone Biologics Announces up to $9.0 Million Private Placement Priced At-The-Market Under Nasdaq Rules
2026-07-08 00:00 · Yahoo
BBLG In Good Shape as Critical Tests Underway
2026-05-15 12:29 · Yahoo
Bone Biologics Improves Extension of rhNELL-1 Product Shelf Life to 24 Months
2025-12-23 13:00 · Yahoo
Bone Biologics Highlights 2025 Key Operational, Scientific, and Corporate Milestones and Provides 2026 Outlook
2026-01-08 13:00 · Yahoo
Bone Biologics Issues Mid-Year Shareholder Update Highlighting Progress Across 2026 Priorities
2026-07-23 12:00 · Yahoo
Bone Biologics Achieves 29-Month Validated Shelf Life for rhNELL-1
2026-05-19 12:00 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.